TransMedics Group’s (TMDX) Overweight Rating Reiterated at Piper Sandler

Piper Sandler restated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Wednesday morning,Benzinga reports. They currently have a $100.00 price objective on the stock, down from their prior price objective of $120.00.

Several other research analysts have also weighed in on TMDX. UBS Group began coverage on shares of TransMedics Group in a research report on Tuesday, July 28th. They set a “neutral” rating and a $80.00 target price on the stock. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Weiss Ratings cut TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $124.18.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $83.89 on Wednesday. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of 21.57 and a beta of 1.90. The business’s 50 day moving average is $73.72 and its two-hundred day moving average is $98.69. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.19 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same period in the prior year, the business earned $0.92 earnings per share. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. Research analysts expect that TransMedics Group will post 1.61 EPS for the current year.

Insider Activity

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Several institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after buying an additional 113,817 shares during the period. Goldman Sachs Group Inc. raised its holdings in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares in the last quarter. Geode Capital Management LLC raised its holdings in TransMedics Group by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after acquiring an additional 2,903 shares in the last quarter. Two Sigma Investments LP boosted its stake in TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after acquiring an additional 171,810 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.